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INTRODUCTION
Resistance to chemotherapy is an important issue in the management of breast cancer patients.
The occurrences of multidrug resistance (MDR) phenotype in patients treated with chemotherapeutic drugs, and sometimes even in their first treatment, limit the therapeutic efficacy. MDR is primarily responsible for the insensitivity of anticancer drugs in metastatic breast cancer (Gottesman 1993) . Resistance may be due to pharmacological, cancer multicellular and unicellular mechanisms. One of the cellular mechanisms is the regulation of the ability of the anticancer agent to reach its intracellular target and its intracellular accumulation operated via efflux mechanisms by a group of transporter proteins. Among these proteins, P-glycoprotein (Pgp) represents the one most thoroughly studied, which is implicated in MDR in-vitro and in-vivo (Leonessa & Clarke 2003) Doxorubicin, a drug of choice for the treatment of breast cancer, has dose limiting cardiotoxicity and its repeated administration may lead to pleiotropic drug resistance in patients. Various agents such as verapamil have been used to overcome the doxorubicin resistance in various clinical studies unsuccessfully. We have previously shown that long-circulating (stealth) monensin liposomes (SML) could enhance the cytotoxicity of anticancer drugs . In order to increase the entrapment of monensin in SML, we had modified our previous method by using pH-gradient method (Shaik et. al., 2001 ) and we also reported that SML prepared by pH-gradient method potentiated the cytotoxicity of doxorubicin, paclitaxel and etoposide in both doxorubicin sensitive and resistant human breast tumor MCF-7 cells . The mechanism(s) by which SML enhances the cytotoxicity of doxorubicin in doxorubicin resistant human breast adenocarcinoma, MCF-7/dox cells was not well studied.
Recently our data indicate that drug resistance may be attributed to the expression of one or more multidrug resistance genes such as multidrugresistance-Pgp (MDR-1), multidrugresistanceassociated protein (MRP-1) and breast cancer resistance protein (BCRP) in MCF-7/dox cells (Leonessa&Clarke, 2003 , Doyle et. al., 1998 . Earlier we have reported that the enhancement of doxorubicine by SML may be mediated via apoptosis and SML-mediated reduction in the expression of multidrugresistance (MDR) genes. Therefore the purpose of this study was to further confirm our observations by performing alternative apoptosis assays to TUNEL studies and also repeating the animal in vivo experiments.
BODY
In our earlier progress report we had described the preparation of stealth monensin liposomes (SML) by pH-gradient method and their characterization for particle size and entrapment efficiency as described by Shaik et al 2001 (3) . We have also reported the effect of the SML on induction of apoptosis in resistant MCF-7 cells and expression of MDR1 and MRP1 in the MCF-7/dox cells. We now have published our work in the journal of Pharmacy and Pharmacology (Shaik et. al., 2004) . For the data to be publishable, we had to repeat several experiments and also perform some additional experiments which have been described below.
Enhancement of the cytotoxicity of anticancer drugs by monensin liposome in MCF-7/dox cells:
The effect of monensin liposomes on enhancement of anticancer drug activity was studied by crystal violet dye uptake method. Briefly, MCF-7/dox cells were seeded at a density of 10,000 cells per well in 96-well plates and incubated overnight. Subsequently, they were treated with various concentrations of doxorubicin/paclitaxel/etoposide alone and in combination with a fixed non-toxic concentration of monensin liposomes (20x1 08 M). Upon treatment, the cells were incubated for 72 hours and the cytotoxicity was assayed by crystal violet dye uptake method by measuring the absorbance at 540 nm (Shaik et al 2001a (Shaik et al , 2001b . Table 1 shows the IC 50 (inhibitory concentration to produce 50% cell kill) values for the anticancer drugs alone and their combination with monensin liposomes. It is evident from Table   1 that MCF-7/dox cell line employed in our study showed 23.3, 2.9 and 132-fold drug resistance (expressed as the ratio of IC 50 in resistant cell line to its parental cell line) to paclitaxel, etoposide and doxorubicin, respectively as compared to its parental MCF-7 cell line. The combination of monensin liposomes (20x1 08 M) with anticancer drugs increased the cell kill resulting in a 2.8, 5.6 and 16.5-fold increase in the cytotoxicity of paclitaxel, etoposide and doxorubicin, respectively against MCF-7/dox cells (Table 1) . These results are in agreement with our previous study in which long-circulating monensin liposomes prepared by conventional method have been shown to increase the cytotoxicity of doxorubicin in MCF-7/dox cells. The current study differs from our previous study in two aspects: (a) MCF-7/dox cells used in the current study have significantly increased resistance to doxorubicin as compared to our previous study and (b) the monensin liposomes employed in the present study were prepared by pH-gradient method. One million MCF-7/dox cells in 10 ml of MEM were plated in 25 cm 2 flask and incubated overnight. Subsequently, they were treated with doxorubicin (2.5 Pig/ml), monensin liposomes (20x10-8 M) and doxorubicin (2.5 tg/ml) with monensin liposomes (20x10-8 M) for 48 hours.
Finally, the specific activity of caspase-3 was estimated using CaspACETM Assay system, colorimetric (Promega Corporation, Madison, WI) as per the manufacturer's protocol.
The specific caspase-3 activity (pmol pNA liberated/h/ýtg protein) in control, doxorubicin (2.5 [tg/ml), monensin liposomes (20 x 10-8 M) and the combination of doxorubicin with monensin liposomes treated cells was found to be 4.9±0. 1999) . Studies were also performed using verapamil (15 ýIg/ml) as a chemosensitizer in place of monensin liposomes essentially in the same way as described above.
We exploited the fluorescent properties of doxorubicin to visually demonstrate the effect of monensin liposomes on doxorubicin accumulation in MCF-7/dox cells, as demonstrated by Kitazone et al (1999) . The cells treated with doxorubicin and monensin liposomes ( Figure 2B) had considerably higher fluorescence as compared with doxorubicin-alone treated cells ( Figure   2A ). We observed an increase in the doxorubicin fluorescence in MCF-7/dox cells treated with doxorubicin and verapamil ( Figure 2C ). After the initial doxorubicin uptake study and further incubation of the cells for 30min in the fresh medium (without doxorubicin), we could still observe the fluorescence ( Figure 2D Our initial observations showed that there was no statistical difference in tumor volumes after treatment with doxorubicin or doxorubicin and SML. These experiments were repeated again and similar results were observed. This led to the following possibilities:
a. SML formulation had no effect on potentiation of doxorubicin in vivo and was acting as a placebo b. The dose of SML needs to be increased for it to show potentiation for doxorubicin.
Possibly the dose of monensin in liposomes is not sufficient for it to lead to a potentiation of doxorubicin as was seen in the in vitro studies.
Since it took a long time to establish the animal studies and the data after several trials was inconclusive, it was deemed necessary to pursue the project further with modifications in protocols with another grant application either for an R01 grant or a similar proposal in collaboration with Dr. Agarwal. Presently this is being developed using some modifications in the protocol.
Key Research Accomplishments 1. SML prepared by pH-gradient method were found to overcome the doxorubicin resistance in MCF-7/dox cells. et al 1996) . However, the lipophilicity and short half-life of Monensin, n-mannitol, l-((+)-trehalose, dipalmitoylphosmonensin precludes its use and therefore, a suitable drug phatidylcholine. cholesterol. stearylamine, doxorubicin, delivery system is needed to obtain the desired in-vivo etoposide. paclitaxel, ciclosporin and all tissue culture effects. Our laboratory has been involved with the devel-media were obtained from Sigma Chemical Company opment of delivery systems for monensin such as long-(St Louis, MO). Distearoyl glycerophospho-ethanolaminecirculating liposomes (Singh etal 1999 (Singh etal , 2001 Shaik etal polyethyleneglycol 2000 was obtained from Avanti Polar 200(la) and nanoparticles (Shaik et al 200t1b DeadEnd Colorimetric Apoptosis Detection System and using a pH-gradient method (Shaik etal 2001a) . Such CaspACE Assay System colorimetric kits were obtained liposomes have been shown to improve the in-vivo anti-from Promega Corporation (Madison, WI). Indornetacin, tumour activity of an immunotoxin in severe combined probenecid and (±)-verapamil hydrochloride were purimmunodeficient mice (Shaik et al 2003) .
chased from MP Biomedicals, Inc. (Aurora, OH). Previous studies showed that chemosensitizers modulated the expression of MDR genes in various drug resisPreparation and characterization of tant tumour cells. Herzog etal (1993) showed that P-gp long-circulating monensin liposomes antagonists such as verapamil, nifedipine and ciclosporin increased the MDRI mRNA levels in drug-resistant colon Monensin liposomes were prepared using a pH-gradient carcinoma cells, whereas another P-gp antagonist, quini-method and characterized for their particle size (BI 90 dine had no effect on MDR1 mRNA levels. However, Particle sizer, Brookhaven Instruments, New York, NY) Muller etal (1995) showed that verapamil reduced and monensin content (by scintillation counting) essen-MDRI gene expression in two leukaemic multidrug resis-tially as described elsewhere (Shaik et al 2001a) . tant cell lines. Beketic-Oreskovic et al (1995) reported that selection of human MES-SA sarcoma cells with doxoru-Reversal of drug resistance in MCF-7/dox cells by bicin and PSC 833 suppressed the emergence of MDR1 monensin liposomes/MDR1 and MRP1 inhibitors mutants. Nielsen etal (2002) showed that the selection of the wild-type Ehrlich ascites tumour cell line (EHR2), MCF-7/dox cells were seeded at a density of 10000 per adapted to grow in the presence of daunorubicin and a well in 96-well plates and incubated overnight. Subcombination of daunorubicin with chemosensitizers (versequently, they were treated with various concentrations apamil and ciclosporin), resulted in a significant decrease of doxorubicin/paclitaxel/etoposide alone and in combiin the levels of MDRla mRNA and P-gp, as compared nation with a fixed non-toxic concentration of monensin with cells selected with daunorubicin alone. Li et al (2001) liposomes (20 x 10-8 m). Upon treatment, the cells were have reported that the treatment of MCF-7/dox cells with incubated for 72h and the cytotoxicity was assayed by nomegestrol showed a time-dependent decrease in the crystal violet dye uptake assay by measuring the absorbexpression of MDRI mRNA levels with a maximum ance at 540nm (Shaik etal 2001a,b) . For experiments decrease observed on the third day, followed by a gradual using known MDRI inhibitors (verapamil and cicloincrease to its normal levels by the tenth day. However, so sporin) and MRPI inhibitors (indometacin and profar there has been no report on the effect of monensin on benecid), the same procedure was followed except that the expression of MDR genes.
the MDRI/MRPI inhibitors were employed at their non-toxic concentrations and used in combination with liposomes (20 x 0-s M) or 2.5 ig nmL' doxorubicin with doxorubicin against MCF-7idox cells. 20 x 10-\M monensin liposomes for 72h and the total RNA was eluted using the Eppendorf Perfect RNA Mini Kit (Brinkman Instruments, Westbury, NY). Reverse Assessment of apoptosis in MCF-7/dox cells by transcription was performed with Moloney-murine leukaemia the combination of doxorubicin with monensin virus reverse transcriptase (MuLV-RT) (Applied Biosystem, liposomes by acridine orange and TUNEL CA) according to the manufacturer's protocol with some ((terminal deoxynucleotidyl transferase-mediated modifications. The PCR reaction was performed with nick end labelling) staining MDRI (sense, 5' CCA TCA TTG CAA TAG CAG G 3'; MCF-7/dox cells were plated into each well of a chamber antisense. 5' GAG CAT ACA TAT GTf CAA ACT T 3'), MCF-/doxcels wee phtedMRPI (sense 5' GGA CCT GGA CTT CGT TCT CA 3'; slide (Nunc Lab-Tek II) at a concentration of 50 000 cells in ( 5' GT CCA GACTT C TC CG 3') 1 mL minimum essential medium (MEM) and allowed to antisense grow overnight. Subsequently, cells were treated with dox-i-actin (sense, 5' GATCATGTTTGAGACCTTC 3'; orubicin (2.5 pg mL-1 ), monensin liposomes (20 x 10-s s), antisense, 5' GTCAGGCAGCTCGTAG 3') primer pairs -) with monensiu and ATAQ DNA polymerase (Applied Biosystem) at 94"C or oxorubicin (2.5gmL )wi nin liposotes
(20 x 10--), and incubated for 72h. The cells were fixed for 2 rin. 30 cycles of94'C, 60.C/52'C for MDRI/MRPI with 0.25" Xv/v glutaraldehyde and the chamber slidc and 72`C (I min each), and then 10min at 72'C before was studied for TUNEL staining using a DeadEnd holding at 4°C. The 126bp for MDRI and 252bp for Colorimetric Apoptosis Detection System kit (Promega) MRPI PCR products were separated in a 1.5% agarose as per the manufacturer's instructions. Finally, the slide gel and the band intensities were normalized with respect to was observed for apoptotic cells under an Olympus BX40 ý3-actin using Scion Image Software (Beta 3b version, Scion microscope equipped with a computer-controlled digital Corporation, Frederick, MD). camera (Qimaging, Burnaby, BC, Canada).
Statistical analysis
Assessment of apoptosis in MCF-7/dox cells One-way analysis of variance followed by Tukey's multiple by caspase-3 assay comparison test was performed to determine the significance of difference in the caspase-3 activity and expression One million MCF-7/dox cells in 10mL MEM were plated levels ofMDRI and MRPI in MCF-7/dox cells subjected to in a 25 cm 2 flask and incubated overnight. Subsequently, various treatments. Statistical analysis was performed using they were treated with doxorubicin (2.5prg mL-1), monen-GraphPad Prism (version 3.0) software (San Diego, CA). sin liposomes (20 x 10-"M), or doxorubicin (2.5 jg mL-') with monensin liposomes (20 x 10-8 M) for 48 h. Finally, the specific activity of caspase-3 was estimated using CaspACE Assay system, colorimetric (Promega Corporation, Results Madison, WI) as per the manufacturer's protocol.
Enhancement of the cytotoxicity of anticancer
Effect of monensin liposomes on fluorescence drugs by monensin liposomes visualization of doxorubicin in MCF-7/dox cells Table I shows the 1C50 (inhibitory concentration to produce 50% cell kill) values for the anticancer drugs alone One million MCF-7/dox cells were plated in each well of a and their combination with monensin liposomes. It was chamber slide and incubated overnight. The cells were then evident that the MCF-7/dox cell line showed 23.3-, 2.9-treated with doxorubicin (10ligmL-1) alone and in combi-and 132-fold drug resistance (expressed as the ratio nation with monensin liposomes (20 x 10-aM) for 30rmin. of IC50 in resistant cell line to its parental cell line) to Subsequently, they were washed with cold phosphate-buf-paclitaxel, etoposide and doxorubicin, respectively, as fered saline (PBS) and examined by fluorescence microscopy compared with its parental MCF-7 cell line (Table 1) . (Olympus BX 40). In another set of experiments, the PBS The combination of monensin liposomes (20 x 10--M) washed cells as described above were incubated in MEM for with anticancer drugs increased the cell kill resulting a further 30 min. Finally, the cells were washed with cold PBS in a 2.8-, 5.6-and 16.5-fold increase in the cytotoxicity and observed under fluorescent microscope equipped with a of paclitaxel, etoposide and doxorubicin, respectively, 520-550 nm excitation and 580 nin emission filter (Kitazono against MCF-7/dox cells ( Table 1) . These results were in etal 1999) . Studies were performed also using verapamil agreement with our previous study (Singh etal 1999) in (15 /pgmL-') as a chemosensitizerin place ofmonensin lipo-which long-circulating monensin liposomes prepared by a somes, essentially in the same way as described above, conventional method were shown to increase the cytotoxicity of doxorubicin in MCF-7/dox cells. This study difInfluence of monensin liposomes on the fered from the previous one in two aspects: MCF-7/dox expression of MDR1/MRP1 in MCF-7/dox cells cells used in this study had significantly increased resistance to doxorubicin as compared with the previous study MCF-7/dox cells (I x 106 in 25 cm 2 flask) were treated with (Singh etal 1999) , and the monensin liposomes employed MEM (control), doxorubicin (2.5 pgmL-1), monensin in this study were prepared by a pH-gradient method. Tlte 1C50 values were expressed ats menan ± s.d. of three independent experiments. *Dru.g resistance reversal I C50 value for drug alone'lC50 value for drug with drugLt resistance muoddier. For combination experiments using mionensin li posornes and M DR inhibitors, the following non-toxic concentrations were used: tisonensin ii iposoles ý20 X 10 'w ciclosporin 6/igtnL 1; veraparnil 15 jig ntL 1; indomectacin 40lpgn. mL pmobenecid ISO jig mL 1. The lC50 values for paclitaxel, etoposide and doxorubicin against doxorubicin sensitive parental MCF-7 cell line were found tu be 0. 18 ± 0.08. 20.9 ± 2.4, (0.2.10.05 jig iL ',respectively-The relative drug, resistance to paclitaxel, etoposide and doxorubicin in MCF-7 ' dox cells was 23.3-. 2.9-and 132-fold, respectively, as compared with MCF-7 cells (expressed ats the ratio of IC50 in MCF-7/dox cells to IC50 in MCF-7 cells).
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Induction of apoptosis in MCF-7/dox cells
IC50 value. Figure I shows the TUNEL staining of MCF-
We studied the induction of apoptosis in MCF-7 '/dox cells 7/dox cells treated with MEM (control), monensin lipoby the combination of monensin liposonses (20 x 10-8m) somes (20 x 10~ "m), doxorubicin (2.5jig mL-) and the with doxorubicin at a concentration much lower thatn its combination treatment of doxotubicin (2.SisgimL7') with monensin liposomes (20 x 10 8m). There was no signifi-doxorubicin-alone treated cells (Figure 2A ). We observed cant apoptosis (< 10%) in the control, doxorubicin and an increase in the doxorubicin fluorescence in MCF-7/dox monensin liposome-treated cells ( Figure I ). On the other cells treated with doxorubicin and verapamil ( Figure 2C) . hand, the combination treatment produced apoptosis After the initial doxorubicin uptake study and further incuin 40% cells. The specific caspase-3 activity (pmol pNA bation of the cells for 30min in the fresh medium (without liberated h-I (pig protein)--I) in control. doxorubicin doxorubicin), we could still observe the fluorescence ( Figure  (2.5 pg mL 1) , monensin liposomes (20 X 10-5 M) and the 2D) in cells initially treated with doxorubicin and monensin combination of doxorubicin (2.5 pgmL-') with monensin liposomes (during the initial loading time). However, we liposomes (20 x 10--M) treated cells was found to be could not detect any fluorescence in the doxorubicin-only 4.9±0.7, 9.9±1.2, 3.9± 1.2 and 20.6±4.0, respectively, treated MCF-7idox cells after 30min of incubation in drugThus, there was a 2.1-fold increase in the caspase-3 activity free medium. These observations suggested that monensin in the cells treated with the combination of doxorubicin liposomes increased the cellular accumulation of doxorubiwith monensin liposomes as compared with doxorubicin-cin from MCF-7idox cells. We had shown previously that only treated cells. The caspase-3 activity in the cells treated the combination of doxorubicin with monensin liposomes with doxorubicin with monensin liposomes was signifiincreased the doxorubicin uptake by more than threefold in cantly different (P < 0.05) as compared with control, dox-a doxorubicin-resistant human promyelocytic leukaemia, orubicin and monensin liposornes treated cells. There was HL-60idox cell-line, as compared with doxorubicin-treated no significant difference in the caspase-3 activity among cells at 30-min period during uptake studies. Furthermore, control, doxorubicin and monensin liposomes treated cells, at post 30-minm period in the efflux study, there was a threefold decrease in the doxorubicin effhix from cells treated with monensin liposomes and doxorubicin as compared Enhanced cellular accumulation of doxorubicin with doxorubicin al cigear9) in MF-7/ox ellsby onenin iposmeswith doxorubicin alone .
in MCF-7/dox cells by monensin liposomes
We exploited the fluorescent properties of doxorubicin to Effect of monensin liposomes on MDR1 and visually demonstrate the effect of monensin liposomes on MRP1 mRNA expression in MCF-7/dox cells doxorubicin accumulation in MCF-7/dox cells, as demonstrated by Kitazone etal (1999) . The cells treated
To study the effect of monensin liposomes on genes with doxorubicin and monensin liposomnes ( Figure 2B) related to the MDR expression, we studied the mRNA had considerably higher fluorescence as compared with expression levels of MDRI and MRPI in MCF-7/dox We chose monensin and doxorubicin as compared with 133 (MDRI) and 157% (MRPI) of at these concentrations because doxorubicin or monensin expression observed with doxorubicin alone. Thus, the at their studied concentrations were nontoxic to cells and combination treatment reduced the doxorubicin-induced did not induce apoptosis, whereas their combination pro-elevated expression of MDRI and MRPI by 70 and 42%, duced a significant apoptotic response (Figure 1) . It was respectively, in MCF-7/dox cells. These results indicated evident from Figure 3 that MCF-7/dox cells expressed that monensin liposomes could inhibit the doxorubicin both MDR1 and MRPI, whereas their expression was induced elevated expression of MDR genes. negligible in the parental MCF-7 cells (data not shown). Semi-quantilative analysis of band intensities followed by F/fect oq 'MDR inhibitors on doxorobicin cvtotoxicity normalization to f3-actin levels, we observed that the expo-in A'ICF-7/dox cells sure of MCF-7/dox cells to doxorubicin increased the To confirm the functional relevance of MDR1 and expression of MDRI and MRPI by 33% (0.62 in control MRPI, we studied the role of known MDRI inhibitors vs 0.83 in doxorubicin-treated cells) and 57% (0.67 in (verapamil and ciclosporin) and MRPI inhibitors (indocontrol vs 1.05 in doxorubicin treated cells), respectively. metacin and probenecid) in overcoming the doxorubicin Monensin liposomes by themselves showed a modest resistance in MCF-7/dox cells. We employed MDR inhidecrease of 10 and 24% in the expression of MDRI and bitors at concentrations which produced cell kill of < 15% MRPI, respectively ( Figure 4 ). The combination treat-and as shown in Table I , all the known MDR inhibitors ment of doxorubicin with monensin liposomes did not were able to enhance the doxorubicin cytotoxicity by decrease the expression of MDRI or MRPI below its 2.8--26.4-fold in MCF-7!dox cells. The results indicated control levels ( Figure 3 ). However, we observed a statisti-that the expression of both MDRI and MRPI contribcally significant difference. in the expression levels of uted to the drug resistance in MCF-7/dox cells and it was MDRI and MRPI in MCF-7idox cells treated with the possible to sensitize these cells to doxorubicin by both combination of doxorubicin and monensin liposomes as MDR] and MRPI inhibitors. However, we observed a shown to significantly decrease the apoptotic response to doxorubicin as compared with its effect in wild-type MCF-7 cells (Li etal 2003) . In this study, we demonDiscussion strated that it was possible to induce apoptosis in MCF-7/dox cells by employing doxorubicin at one-tenth In recent years enormous efforts have been directed to of its IC50 value in combination with monensin lipofind drug transport-modulating agents to circumvent P-somes (Figure 1 ). Caspase-3 activation is an early event gp and MRP-mediated drug resistance. Compounds such in the apoptosis cascade, whereas its activation triggers as verapamil, ciclosporin, qunidine, resperpine and other PARP cleavage, which is parallel to apoptosis detection by compounds have been shown to overcome MDR in-vitro. DNA degradation and TUNEL assays (Li etal 2001) . However, most of these compounds have disappointing Accordingly, caspase-3 estimation was carried out early results in animal studies because of toxicity considera-at 48 h as compared with the TUNEL assay performed at tions. Accordingly, new agents with low toxicity and 72h after drug treatment. Our data supports the theory high reversal activity are being actively evaluated (Li that monensin liposomes can sensitize the MCF-7/dox etal 2001; Toppmeyer eta! 2002) . The carboxylic iono-cells to doxorubicin and induce apoptosis via caspase-3 phore monensin has been shown to overcome drug resis-activation. However, the molecular mechanisms leading tance in several tumour cell lines (Sehested etal 1988) . The to apoptosis needs to be elucidated further. short half-life and lipophilicity of monensin precluded
We reported (Singh etal 1999) that monensin lipoits further use in in-vivo studies. Other workers have somes increased the doxorubicin uptake and decreased attempted to synthesize various monensin derivatives its efflux in HL-60'dox cells. In this study, we have (Dosio etal 1996) or monensin conjugates (Colombatti shown morphological evidence for the increased cellular etal 1990). Our laboratory pursued a drug delivery accumulation of doxorubicin in MCF-7/dox cells treated approach for monensin to overcome its shortcomings with doxorubicin and monensin liposomes ( Figure 2 ). and developed long-circulating nanoparticulate and lipo-Previous studies have shown that monensin (101om) somal formulations of monensin (Singh etal 1999: Shaik increased the uptake of anthracycline antibiotics in drug et a! 2001a,b). Recently, we demonstrated the potential of resistant cells (Wood etal 1996; Cleary etal 1997) . We long-circulating liposomes in enhancing the in-vivo cyto-have consistently observed enhancement of doxorubicin toxicity of anti-My9-bR immunotoxin (Shaik et al 2003) .
cytotoxicity and altered cellular kinetics in MCF-7/dox The MCF-7/dox cells employed in our study were made cells at a significantly much lower concentration (200t nM) resistant to doxorubicin by growing them in the presence of by delivering monensin in the form of liposomes as corndoxorubicin (600 ngmL-1). The 1C50 value for doxorubi-pared with the concentrations ofmonensin delivered as a cin against MCF-7/dox cells was 26.5 tigmL-', which was solution (Singh etal 1999; Shaik etal 2001b) . Studies by 1.5-fold the reported value for a similar type of doxorubi-Naito et al (1991) showed that ionophores such as moncin-resistant MCF-7 cell employed by Li etal (2001) . ensin inhibited the binding of vincristine to plasma memConsistent with the reported findings that cells made resis-brane isolated from resistant K562 cells and reduced the tant to a particular drug also acquire resistance to other photoaffinity labelling of P-gp by azidopine. Wood etal classes of drug. we observed that our MCF-7/dox cells (1996) proposed that the drug resistance modification by exhibited 2.9-23.3-fold resistance to etoposide and pacli-monensin might be due to its binding to P-gp, rather than taxel, respectively, as compared with the parental MCF-7 interfering with vesicular traffic. In the light of recent cells. As shown in Table 1 , monensin liposomes were able studies demonstrating the modulation of various MDR to increase the sensitivity of MCF-7/dox cells not only for genes by chemosensitizing agents (Li etal 2001) , we studoxorubicin but also to paclitaxel and etoposide. One died the expression of MDRI and MRPI genes in MCFadvantage of using monensin liposomes was that they 7/dox cells. We observed that MCF-7/dox cells expressed worked in-vitro at fairly low concentrations (20 x 10-M both MDRI and MRPI genes by RT-PCR. Significant or 200 riM) as compared with other reported chemosensiti-expression of both MDR1 and MRP1 in MCF-7/dox cells zers, which work in various drug resistant human breast had been reported by Chauvier et al (2002) . We found that and other tumour cell lines. Chemosensitizers such as monensin liposomes alone had a moderate effect, whereas nomogestrol, megestrol, droloxifen and verapamil work at doxorubicin treatment alone had significantly increased 201dM (Li etal 2001) , whilst VX-710 works at 0.5-2.5pM the expression of MDR genes. However, the combination (Germann etal 1997). Another chemosensitizer MS-209 of doxorubicin with monensin liposomes showed a works at 1-101iM (Naito etal 2002) , and PSC 833 works decrease in the expression of both MDRI and MRPI at 1-31tM (Warmann etal 2002) . Previously, we reported gene expression as compared with doxorubicin alone the potential of monensin liposomes in overcoming dox- (Figure 3 ). Warmann et al (2002) reported that doxorubiorubicin resistance in a human promyelocytic leukaemia cin treatment increased the expression of MDRI in hepacell line, HL-60/dox (Shaik et al 200 1c) .
toblastoama Hep TI cells. However, their data showed no Recent studies suggested that the occurrence of MDR alteration in MDRI expression in cells treated with doxin cancer cells may be the result of a decrease in the ability orubicin in the presence of chemosensitizers such as of the cancer cells to initiate apoptosis in response to verapamil or PSC 833 as compared with doxorubicin cytotoxic agents (Jones eta! 2002) . Over-expression of alone. Borrel etal (1994) reported that monensin formed
